GI Innovation Announces Administrative Resubmission of IND to FDA Due to Review Division Reassignment... Phase 1b/2 Trial of Combination Therapy with Janssen
Due to FDA review division reassignment, the IND submission was resubmitted on May 28, 2026, as an administrative procedure without substantive changes.
The trial is conducted under a Clinical Trial Collaboration and Supply Agreement signed with Janssen Research & Development, LLC on March 17, 2026.
The target indication is metastatic castration-resistant prostate cancer (mCRPC). This is a phase 1b/2 open-label, multicenter trial evaluating safety and anti-tumor activity of GI-102 in combination with pasritamig.
Clinical sites include Severance Hospital and Asan Medical Center in South Korea, and Columbia University Irving Medical Center in the US. Target enrollment is up to 107 patients, with an estimated duration of about 3 years.
The IND submission date is May 28, 2026. This is an administrative resubmission per FDA request, with no change in the IND content.
The trial targets patients who failed prior novel hormonal therapy (NHT). Statistical probability of eventual approval is approximately 10%, highlighting investment risks.
[AI Comprehensive Analysis]This disclosure reflects an administrative change due to FDA division reassignment, with no negative impact on trial progress but also no positive catalyst. Near-term stock price impact is limited; long-term key variables include clinical results of the combination therapy and collaboration outcomes with Janssen.
KOSDAQ Filing Information
Filing: [Correction of Description]Material Information Related to Investment Decision (Clinical Trial Plan Approval Application) (Application for Approval of a Phase 1b/2 Clinical Trial to Evaluate the Antitumor Activity, Safety, and Tolerability of GI102 in Combination with Pasritamig in Patients with Metastatic Castration-Resistant Prostate Cancer)